CORDIS · 115009 · FP7
PHARMA-COG Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development
Coordinator: GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED (UK)
PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision before entering phase II trials for both symptomatic treatment and disease modifiers approaches. The hypothesis is that effective long term drugs will normalize markers artificially modified. The genera…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
Co-funding: the European Union contributes €9.7M toward a total project budget of €30.7M — a funding rate of 31%, with the remainder covered by the consortium partners. The project runs over approximately 6 years from 2010-01-01 to 2015-12-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from UK
see all →- ENABLE — European Gram Negative Antibacterial Engine115583 · FP7 · €58.9M
- EBOVAC1 — Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime-Boost Regimen – Sofia ref.: 115854115854 · H2020 · €58.3M
- CRESCENDO — Collaborative & Robust Engineering using Simulation Capability Enabling Next Design Optimisation234344 · FP7 · €32.5M
- H2ME — Hydrogen Mobility Europe671438 · H2020 · €32.0M
- JIVE — Joint Initiative for hydrogen Vehicles across Europe735582 · H2020 · €32.0M
- LIGAND-AI — Protein-ligand data generation at scale to support computational hit finding and optimization101252959 · HORIZON · €29.9M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
- GSC DA — GMES Space Component Data Access223001 · FR · €48.0M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the JTI-CP-IMI funding scheme.
- What is the EU contribution?
- The European Commission contributes €9.7M toward a total project budget of €30.7M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED (UK).
- What is the project timeline?
- The project runs from 2010-01-01 to 2015-12-31 — approximately 6 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 115009.